Lowest Price Guaranteed From USD 4,899
Published
July 2020
Pages
460
View Count
19870
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
With close to 80 monoclonal antibodies approved till date, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become an important part of the biopharmaceutical industry. In fact, they are presently estimated to constitute the largest class of biologics in the industry. Examples of recently approved monoclonal antibody products include (in reverse chronological order) Adakveo® (November 2019), Beovu® (October 2019), SKYRIZI™ (April 2019) and EVENITY™ (April 2019). These molecules have high target specificities and favorable safety profiles. Further, given the success of monoclonal antibodies, research on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, has also gained traction.
The development of such biologics is inherently complex, and many drug developers are now seeking to optimize R&D efficiency and affiliated costs. As a result, innovator companies are outsourcing most of their discovery-stage operations to specialty contract research organizations (CROs). Modern CROs are known to offer a plethora of advanced technologies to cater to the evolving needs. Apart from being considered a viable business strategy, engaging third party service providers offers both time and cost related benefits to drug / therapy developers. Therefore, as the demand for antibody based therapeutic / diagnostic products increases, the opportunity for contract service provides and technology developers is also anticipated to rise steadily in the foreseen future.
The “Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years. The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics. In addition to other elements, it includes:
One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade. Based on parameters, such as the overall R&D expenditure available to CROs, percentage of R&D expenses incurred in each discovery step, and outsourcing profile, we have provided an informed estimate of the likely evolution of the antibody discovery services market in the mid to long term, for the time period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within antibody discovery services market across [A] the various steps involved in antibody discovery process (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery methods (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). In addition, for estimating the future market opportunities for platform providers, we have considered the likely licensing deal structures and agreements that are expected to be inked in the foreseen future. The future opportunities within the antibody discovery platforms market has been segmented across key geographical regions (North America, Europe and Asia- Pacific). The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the antibody discovery services and platform market and its evolution in the short-mid-term and long term.
Chapter 3 provides a general introduction of antibodies featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes on the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.
Chapter 4 features a detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also highlights a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.
Chapter 5 provides a general overview of the current market landscape of more than 80 service providers that are currently active in this domain. It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).
Chapter 6 provides an insightful competitiveness analysis of antibody discovery service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on the year of establishment of the service provider) and service strength (which takes into account the number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed).
Chapter 7 provides detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery services, recent developments and an informed future outlook.
Chapter 8 presents the current market landscape of over 120+ antibody discovery platform providers, including information on their company details such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of 170+ antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.
Chapter 9 provides an insightful competitiveness analysis of antibody discovery platforms. It highlights the leading players in this domain, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as types of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform (2015-2020).
Chapter 10 provides detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery technology / platforms to other companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery technology / platforms, recent developments and an informed future outlook
Chapter 11 presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered for platform providers.
Chapter 12 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in this market in the time period between 2015 and 2020 (till March). It includes a brief description of partnership models (such as acquisitions, product development agreements, product integration agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, and service agreements) adopted by the stakeholders.
Chapter 13 presents an analysis of the investments made in this domain during the period 2016-2020 (till April), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of discovery in companies that are focused on antibody discovery.
Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of antibody discovery services domain till the year 2030. In order to provide details on the future opportunities, our projections have been segmented on the basis of [A] the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world).
Chapter 15 presents the likely growth of antibody discovery platform market, on the basis of licensing deal structures and agreements signed or planned in the foreseen future. In order to provide details on the future opportunities, the projections have been segmented on the basis of
key geographical regions (North America, Europe and Asia- Pacific).
Chapter 16 features detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2018). It provides information on top five drugs, namely Humira®, Keytruda®, Herceptin®, Avastin® and Rituxan®, their historical sales, and discovery process and methods.
Chapter 17 features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents a list of key players along with the information on their respective location, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models adopted by the players involved in this domain. In addition, chapter provides insights on a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.
Chapter 18 provides an overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry’s evolution over the coming decade.
Chapter 19 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of person name) Tracey Mullen (Chief Executive Officer, Abveris Antibody), Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences), Mark Kubik (Chief Business Officer, AvantGen), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Sanjiban K Banerjee (Director, AbGenics Life Sciences), Ignacio Pino (Chief Executive Officer and President, CDI Laboratories), Jeng Her (Chief Executive Officer, AP Biosciences), Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Aaron Sato (Chief Scientific Officer, LakePharma / Twist Biosciences)
Chapter 20 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it highlights the various evolutionary trends that are likely to determine the future of this segment of the antibody discovery service and platform market.
Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Development
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Polyclonal Antibodies
3.6.3. Bispecific Antibodies
3.7. Applications of Antibodies
4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3. Transgenic Animal-Based Method
4.3.4. Single B Cell-Based Method
4.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
4.4. Evolution of Monoclonal Antibodies
4.4.1. Fully Human Monoclonal Antibodies
5. ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Service Offered
5.2.5. Analysis by Type of Antibody Discovery Method
5.2.6. Grid Representation: Analysis by Type of Service Offered, Type of Antibody Discovery Method and Company Size
5.2.7. Analysis by Animal Model Used
5.2.8. Analysis by Type of Antibody Discovered
5.2.9. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
5.2.10. Analysis by Purpose of Antibody Discovery
5.2.11. Analysis by Type of Antibody Discovery Method and Purpose of Antibody Discovery
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Competitiveness Analysis: Antibody Discovery Service Providers
6.4.1. Antibody Discovery Service Providers based in North America
6.4.2. Antibody Discovery Service Providers based in Europe
6.4.3. Antibody Discovery Service Providers based in Asia Pacific
7. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers in North America
7.2.1. Abwiz Bio
7.2.1.1. Company Overview
7.2.1.2. Antibody Discovery Services
7.2.1.3. Recent Developments and Future Outlook
7.2.2. Aragen Bioscience (A GVK BIO Company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services
7.2.2.3. Recent Developments and Future Outlook
7.2.3. Distributed Bio
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services
7.2.3.3. Recent Developments and Future Outlook
7.2.4. Integral Molecular
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services
7.2.4.3. Recent Developments and Future Outlook
7.2.5. LakePharma
7.2.5.1. Company Overview
7.2.5.2. Antibody Discovery Services
7.2.5.3. Recent Developments and Future Outlook
7.3. Antibody Discovery Service Providers in Europe
7.3.1. Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services
7.3.1.4. Recent Developments and Future Outlook
7.3.2. ImmunoPrecise Antibodies
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Antibody Discovery Services
7.3.2.4. Recent Developments and Future Outlook
7.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services
7.3.3.3. Recent Developments and Future Outlook
7.4. Antibody Discovery Service Providers in Asia-Pacific
7.4.1. ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services
7.4.1.3. Recent Developments and Future Outlook
7.4.2. Viva Biotech
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Antibody Discovery Services
7.4.2.4. Recent Developments and Future Outlook
7.4.3. WuXi Biologics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. Antibody Discovery Services
7.4.3.4. Recent Developments and Future Outlook
8. ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Antibody Discovery Platform Providers: List of Industry Players
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Antibody Discovered
8.3. Antibody Discovery: List of Technologies and Platforms
8.3.1. Analysis by Type of Antibody Discovery Method
8.3.2. Analysis by Type of Antibody Discovery Method and Location of Headquarters
8.3.3. Analysis by Animal Model Used
8.3.4. Analysis by Patent Availability
9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Key Parameters
9.4. Technology Competitiveness Analysis: Antibody Discovery Platforms
9.4.1 Competitiveness Analysis: Library Based Antibody Discovery Platforms
9.4.2. Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
9.4.3. Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
9.4.4. Competitiveness Analysis: Other Antibody Discovery Platforms
10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. ImmunoPrecise Antibodies
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Portfolio of Antibody Discovery Platforms
10.2.3.1. Abthena™
10.2.3.2. B cell Select™
10.2.3.3. DeepDisplay™
10.2.3.4. ModiFuse™
10.2.3.5. ModiPhage™
10.2.3.6. ModiSelect™
10.2.3.7. ModiTune™
10.2.4. Recent Developments and Future Outlook
10.3. Harbour BioMed
10.3.1. Company Overview
10.3.2. Portfolio of Antibody Discovery Platforms
10.3.2.1. H2L2 Platform
10.3.2.2. HCAb Platform
10.3.3. Recent Developments and Future Outlook
10.4. Kymab
10.4.1. Company Overview
10.4.2. Portfolio of Antibody Discovery Platforms
10.4.2.1. Kymouse™
10.4.2.2. IntelliSelect®
10.4.3. Recent Developments and Future Outlook
10.5. Ligand Pharmaceuticals
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Portfolio of Antibody Discovery Platforms
10.5.3.1. OmniAb®
10.5.3.1.1. OmniChicken®
10.5.3.1.2. OmniClic™
10.5.3.1.3. OmniFlic®
10.5.3.1.4. OmniMouse®
10.5.3.1.5. OmniRat®
10.5.4. Recent Developments and Future Outlook
10.6. MorphoSys
10.6.1. Company Overview
10.6.2. Financial Information
10.6.3. Portfolio of Antibody Discovery Platforms
10.6.3.1. arYla® Technology
10.6.3.2. HuCAL® Technology
10.6.3.3. Ylanthia® Technology
10.6.4. Recent Developments and Future Outlook
11. REGIONAL CAPABILITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Regional Capability Analysis: Antibody Discovery Service Providers
11.3.1 Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in North America
11.3.2. Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Europe
11.3.3. Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Asia-Pacific
11.4. Regional Capability Analysis: Antibody Discovery Platform Providers
11.4.1. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in North America
11.4.2. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Europe
11.4.3. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Asia-Pacific
11.5. Concluding Remarks
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by the Type of Company (Service / Platform Providers)
12.3.4. Analysis by Type of Antibody Discovered
12.3.5. Analysis by Year of Partnership and Type of Partner
12.3.6. Analysis by Type of Partnership and Type of Partner
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Most Popular Technologies: Analysis by Number of Partnerships
12.3.9. Regional Analysis
12.3.9.1. Intercontinental and Intracontinental Agreements
13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
13.3.1. Analysis by Number of Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Active Players: Analysis by Amount Invested
13.3.5. Most Active Investors: Analysis by Number of Funding Instances
13.3.6. Regional Analysis by Amount Invested
13.4. Concluding Remarks
14. ANTIBODY DISCOVERY SERVICES: MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Global Antibody Discovery Services Market, 2020-2030
14.4. Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030
14.4.1. Antibody Discovery Services Market for Antigen Designing, 2020-2030
14.4.2. Antibody Discovery Services Market for Hit Generation, 2020-2030
14.4.3. Antibody Discovery Services Market for Lead Selection, 2020-2030
14.4.4. Antibody Discovery Services Market for Lead Optimization, 2020-2030
14.4.5. Antibody Discovery Services Market for Lead Characterization, 2020-2030
14.5. Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030
14.5.1. Antibody Discovery Services Market for Phage Display, 2020-2030
14.5.2. Antibody Discovery Services Market for Yeast Display, 2020-2030
14.5.3. Antibody Discovery Services Market for Hybridoma Method, 2020-2030
14.5.4. Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030
14.5.5. Antibody Discovery Services Market for Single Cell Based Method, 2020-2030
14.5.6. Antibody Discovery Services Market for Other Methods, 2020-2030
14.6. Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030
14.6.1. Antibody Discovery Services Market for Humanized Antibodies, 2020-2030
14.6.2. Antibody Discovery Services Market for Human Antibodies, 2020-2030
14.6.3. Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030
14.6.4. Antibody Discovery Services Market for Murine Antibodies, 2020-2030
14.7. Global Antibody Discovery Services Market: Distribution by Region, 2020-2030
14.7.1. Antibody Discovery Services Market in North America, 2020-2030
14.7.2. Antibody Discovery Services Market in Europe, 2020-2030
14.7.3. Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
14.7.4. Antibody Discovery Services: Market Attractiveness Analysis by Region
15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST
15.1. Chapter Overview
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Antibody Discovery Platforms Market, 2020-2030
15.5. Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030
15.5.1. Antibody Discovery Platforms Market in North America, 2020-2030
15.5.2. Antibody Discovery Platforms Market in Europe, 2020-2030
15.5.3. Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030
16. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
16.1. Chapter Overview
16.2. Humira® (Adalimumab)
16.2.1. Drug Overview
16.2.2. Discovery Process and Method
16.2.3. Historical Sales
16.3. Keytruda® (Pembrolizumab)
16.3.1. Drug Overview
16.3.2. Discovery Process and Method
16.3.3. Historical Sales
16.4. Herceptin® (Trastuzumab)
16.4.1. Drug Overview
16.4.2. Discovery Process and Method
16.4.3. Historical Sales
16.5. Avastin® (Bevacizumab)
16.5.1. Drug Overview
16.5.2. Discovery Process and Method
16.5.3. Historical Sales
16.6. Rituxan® (Rituximab)
16.6.1. Drug Overview
16.6.2. Discovery Process and Method
16.6.3. Historical Sales
17. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
17.1. Importance of Antibody Humanization and Affinity Maturation
17.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
17.3. Antibody Humanization: Publication Analysis
17.3.1. Publication Analysis: Year-Wise Trend
17.3.2. Publication Analysis: Key Journals
17.3.3. Publication Analysis: Distribution by Animal Model Used
17.3.4. Publication Analysis: Distribution by Method Used for Humanization
17.4. Antibody Humanization Service and Platform Providers: SWOT Analysis
18. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
18.1. Chapter Overview
18.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Formats
18.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
18.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
18.5. Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications
18.6. Growing Market Opportunities in the Asia-Pacific Region
18.7. Expected Increase in Number of Collaborations and Licensing Activity
18.8 Concluding Remarks
19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Abveris Antibody
19.2.1. Company Snapshot
19.2.2. Tracey Mullen, Chief Executive Officer (Q2 2020)
19.3. Nidus Biosciences
19.3.1. Company Snapshot
19.3.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)
19.4. AvantGen
19.4.1. Company Snapshot
19.4.2. Mark Kubik, Chief Business Officer(Q1 2020)
19.5. Single Cell Technology
19.5.1. Company Snapshot
19.5.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)
19.6. Distributed Bio
19.6.1. Company Snapshot
19.6.2. Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)
19.7. AbCellera
19.7.1. Company Snapshot
19.7.2. Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)
19.8. AbGenics Life Sciences
19.8.1. Company Snapshot
19.8.2. Sanjiban K Banerjee, Director (Q2 2018)
19.9. CDI Laboratories
19.9.1. Company Snapshot
19.9.2. Ignacio Pino, Chief Executive Officer and President (Q2 2017)
19.10. AP Biosciences
19.10.1. Company Snapshot
19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)
19.11. YUMAB
19.11.1. Company Snapshot
19.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
19.12. Antibody Solutions
19.12.1. Company Snapshot
19.12.2. Debra Valsamis, Business Development Associate (Q2 2017)
19.13. Ligand Pharmaceuticals
19.13.1. Company Snapshot
19.13.2. Christel Iffland, Vice President (Q2 2017)
19.14. LakePharma
19.14.1. Company Snapshot
19.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)
20. CONCLUDING REMARKS
20.1. Chapter Overview
20.2. Key Takeaways
21. APPENDIX 1: TABULATED DATA
22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
Figure 3.1 Basic Structure of an Antibody
Figure 3.2 Historical Timeline of Antibody Development
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Applications of Antibodies
Figure 4.1 Overview of the Antibody Discovery Process
Figure 4.2 Antibody Discovery Process: Hybridoma Method
Figure 4.3 Antibody Discovery Process: Phage Display Method
Figure 4.4 Antibody Generation Using Transgenic Animals
Figure 4.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 4.6 Approval Timeline of Fully Human Monoclonal Antibody Therapeutics
Figure 4.7 Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Figure 5.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 5.2 Antibody Discovery Service Providers: Distribution by Company Size
Figure 5.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Figure 5.4 World Map Representation: Analysis by Location by Headquarters
Figure 5.5 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Figure 5.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 5.7 Grid Representation: Distribution by Type of Service Offered, Type of Antibody Discovery Method and Company Size
Figure 5.8 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 5.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Figure 5.10 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method and Type of Antibody Discovered
Figure 5.11 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Figure 5.12 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method and Purpose of Antibody Discovery
Figure 6.1 Competitiveness Analysis: Antibody Discovery Service Providers based in North America
Figure 6.2 Competitiveness Analysis: Antibody Discovery Service Providers based in Europe
Figure 6.3 Competitiveness Analysis: Antibody Discovery Service Providers based in Asia-Pacific
Figure 7.1 Abzena: Annual Revenues, 2014-2018 (GBP Million)
Figure 7.2 ImmunoPrecise Antibodies: Annual Revenues, 2016-9M 2020 (USD Million)
Figure 7.3 Viva Biotech: Annual Revenues, 2016-2019 (RMB Million)
Figure 7.4 Wuxi Biologics: Annual Revenues, 2015-2019 (RMB Billion)
Figure 8.1 Antibody Discovery Platform Providers: Distribution by Year of Establishment
Figure 8.2 Antibody Discovery Platform Providers: Distribution by Company Size
Figure 8.3 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
Figure 8.4 World Map Representation: Analysis by Location by Headquarters
Figure 8.5 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Figure 8.6 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Figure 8.7 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Figure 8.8 Antibody Discovery Platforms: Distribution by Animal Model Used
Figure 8.9 Antibody Discovery Platforms: Distribution by Patent Availability
Figure 9.1 Competitiveness Analysis: Library Based Antibody Discovery Platforms
Figure 9.2 Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
Figure 9.3 Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
Figure 9.4 Competitiveness Analysis: Other Antibody Discovery Platforms
Figure 10.1 ImmunoPrecise Antibodies: Annual Revenues, 2016-9M 2020 (USD Million)
Figure 10.2 Ligand Pharmaceuticals: Annual Revenues, 2014-3M 2020 (USD Million)
Figure 10.3 MorphoSys: Annual Revenues, 2014-3M 2020 (USD Million)
Figure 11.1 Regional Capability Analysis: Antibody Discovery Service Providers based in North America
Figure 11.2 Regional Capability Analysis: Antibody Discovery Service Providers based in Europe
Figure 11.3 Regional Capability Analysis: Antibody Discovery Service Providers based in Asia-Pacific
Figure 11.4 Regional Capability Analysis: Concluding Remarks
Figure 12.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2020
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
Figure 12.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 12.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 12.8 Most Active Players: Distribution by Number of Partnerships
Figure 12.9 Most Popular Technologies: Distribution by Number of Partnerships
Figure 12.10 Partnership and Collaborations: Regional Distribution
Figure 12.11 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 13.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2020
Figure 13.2 Funding and Investment Analysis: Year-wise Distribution of Instances by Platform / Service Providers, (2016-2020)
Figure 13.3 Funding and Investment Analysis: Cumulative Amount Invested, 2016-2020 (USD Million)
Figure 13.4 Funding and Investment Analysis: Distribution by Instances Across the Amount Invested, 2016-2020 (USD Million)
Figure 13.5 Funding and Investment Analysis: Year-wise Distribution of the Amount Invested by Platform / Service Providers, 2016-2020 (USD Million)
Figure 13.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2016-2020
Figure 13.7 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2016-2020 (USD Million)
Figure 13.8 Funding and Investment Analysis: Summary of Investments, 2016-2020 (USD Million)
Figure 13.9 Funding and Investment Analysis: Most Active Players, 2016–2020 (USD Million)
Figure 13.10 Funding and Investment Analysis: Most Active Investors
Figure 13.11 Funding and Investment Analysis: Distribution by Geography
Figure 13.12 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 13.13 Funding and Investment Summary, 2016-2020 (USD Million)
Figure 14.1 Global Antibody Discovery Services Market, 2020-2030 (USD Billion)
Figure 14.2 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030
Figure 14.3 Antibody Discovery Services Market for Antigen Designing, 2020-2030
Figure 14.4 Antibody Discovery Services Market for Hit Generation, 2020-2030
Figure 14.5 Antibody Discovery Services Market for Lead Selection, 2020-2030
Figure 14.6 Antibody Discovery Services Market for Lead Optimization, 2020-2030
Figure 14.7 Antibody Discovery Services Market for Lead Characterization, 2020-2030
Figure 14.8 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030
Figure 14.9 Antibody Discovery Services Market for Phage Display, 2020-2030
Figure 14.10 Antibody Discovery Services Market for Yeast Display, 2020-2030
Figure 14.11 Antibody Discovery Services Market for Hybridoma Method, 2020-2030
Figure 14.12 Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030
Figure 14.13 Antibody Discovery Services Market for Single Cell Based Method, 2020-2030
Figure 14.14 Antibody Discovery Services Market for Other Methods, 2020-2030
Figure 14.15 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030
Figure 14.16 Antibody Discovery Services Market for Humanized Antibodies, 2020-2030
Figure 14.17 Antibody Discovery Services Market for Human Antibodies, 2020-2030
Figure 14.18 Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030
Figure 14.19 Antibody Discovery Services Market for Murine Antibodies, 2020-2030
Figure 14.20 Global Antibody Discovery Services Market: Distribution by Region, 2020-2030
Figure 14.21 Antibody Discovery Services Market in North America, 2020-2030
Figure 14.22 Antibody Discovery Services Market in Europe, 2020-2030
Figure 14.23 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
Figure 14.24 Antibody Discovery Services: Market Attractiveness Analysis by Region
Figure 15.1 Licensing Agreements: Distribution of Financial Components
Figure 15.2 Technology Licensing Deal: Payment Structure
Figure 15.3 Global Antibody Discovery Platforms Market, 2020-2030 (USD Million)
Figure 15.4 Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030 (USD Million)
Figure 15.5 Antibody Discovery Platforms Market in North America, 2020-2030
Figure 15.6 Antibody Discovery Platforms Market in Europe, 2020-2030
Figure 15.7 Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030
Figure 16.1 Humira®: Annual Sales, 2013-2019 (USD Billion)
Figure 16.2 Keytruda®: Annual Sales, 2014-2019 (USD Billion)
Figure 16.3 Herceptin®: Annual Sales, 2013-2019 (USD Billion)
Figure 16.4 Avastin®: Annual Sales, 2013-2019 (USD Billion)
Figure 16.5 Rituxan®: Annual Sales, 2013-2019 (USD Billion)
Figure 17.1 Publication Analysis: Quarterly Distribution
Figure 17.2 Publication Analysis: Distribution by Key Journals
Figure 17.3 Publication Analysis: Distribution by Study Model
Figure 17.4 Publication Analysis: Distribution by Method Used for Humanization
Figure 17.6 Antibody Humanization Service and Platform Providers: SWOT Analysis
Figure 17.7 Antibody Humanization Service and Platform Providers: Strengths Overview
Figure 17.8 Antibody Humanization Service and Platform Providers: Weaknesses Overview
Figure 17.9 Antibody Humanization Service and Platform Providers: Opportunities Overview
Figure 17.10 Antibody Humanization Service and Platform Providers: Threats Overview
Figure 18.1 Future Opportunities Related to Upcoming Trends in Drug Discovery
Figure 18.2 Number of Licensing Deals, 2015- 2020
Table 3.1 Antibody Isotypes: Key Features
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
Table 3.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 4.1 Antibody Discovery Methods: Advantages and Disadvantages
Table 4.2 List of Approved Monoclonal Antibodies
Table 5.1 List of Antibody Discovery Service Providers
Table 5.2 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 5.3 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 5.4 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 5.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 5.6 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Table 7.1 Antibody Discovery Service Providers: List of Companies Profiled
Table 7.2 Abwiz Bio: Recent Developments and Future Outlook
Table 7.3 Aragen Bioscience: Recent Developments and Future Outlook
Table 7.4 Distributed Bio: Recent Developments and Future Outlook
Table 7.5 Integral Molecular: Recent Developments and Future Outlook
Table 7.6 LakePharma: Recent Developments and Future Outlook
Table 7.7 Abzena: Recent Developments and Future Outlook
Table 7.8 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 7.9 PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group): Recent Developments and Future Outlook
Table 7.10 ChemPartner: Recent Developments and Future Outlook
Table 7.11 Viva Biotech: Recent Developments and Future Outlook
Table 7.12 Wuxi Biologics: Recent Developments and Future Outlook
Table 8.1 List of Antibody Discovery Platform Providers
Table 8.2 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Table 8.3 Antibody Discovery: List of Technologies and Platforms
Table 8.4 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Table 8.5 Antibody Discovery Platforms: Distribution by Animal Model Used
Table 8.6 Antibody Discovery Platforms: Distribution by Patent Availability
Table 10.1 Antibody Discovery Platform Providers: List of Companies Profiled
Table 10.2 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 10.3 Harbour BioMed: Recent Developments and Future Outlook
Table 10.4 Kymab: Recent Developments and Future Outlook
Table 10.5 OmniAb® Technology: Patent Information
Table 10.6 OmniChicken® Technology: Patent Information
Table 10.7 Ligand Pharmaceuticals: Recent Developments and Future Outlook
Table 10.8 MorphoSys: Recent Developments and Future Outlook
Table 11.1 Regional Capability Analysis: Antibody Discovery Platform Providers based in North America
Table 11.2 Regional Capability Analysis: Antibody Discovery Platform Providers based in Europe
Table 11.3 Regional Capability Analysis: Antibody Discovery Platform Providers based in Asia-Pacific
Table 12.1 Antibody Discovery Service and Platform Providers: Partnerships and Collaboration, 2015-2020
Table 13.1 Antibody Discovery Service and Platform Providers: Funding and Investment, 2016-2020
Table13.2 Funding and Investment Analysis: Summary of Investments
Table 15.1 Developmental / Regulatory Milestones
Table 15.2 Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
Table 16.1 Top Ten Selling Therapeutic Antibodies, 2018
Table 17.1 Approved Monoclonal Antibodies: Information on Affinity
Table 17.2 Antibody Humanization and Affinity Maturation: Service and Platform Providers
Table 17.3 Antibody Humanization and Affinity Maturation: Description of Services and Platform Providers
Table 17.4 Antibody Humanization: Recent Publications
Table 17.5 Antibody Humanization: Modified CDR Grafting Methods
Table 18.1 Antibody Discovery Services and Platform Providers: Asia-Pacific Region
Table 19.1 Company Snapshot: Abveris Antibody
Table 19.2 Company Snapshot: Nidus Biosciences
Table 19.3 Company Snapshot: AvantGen
Table 19.4 Company Snapshot: Single Cell Technology
Table 19.5 Company Snapshot: Distributed Bio
Table 19.6 Company Snapshot: AbCellera
Table 19.7 Company Snapshot: AbGenics Life Sciences
Table 19.8 Company Snapshot: CDI Laboratories
Table 19.9 Company Snapshot: AP Biosciences
Table 19.10 Company Snapshot: YUMAB
Table 19.12 Company Snapshot: Antibody Solutions
Table 19.13 Company Snapshot: Ligand Pharmaceuticals
Table 19.14 Company Snapshot: LakePharma
Table 21.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 21.2 Antibody Discovery Service Providers: Distribution by Company Size
Table 21.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Table 21.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 21.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 21.6 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 21.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 21.8 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Table 21.9 Abzena: Annual Revenues, 2014-2018 (GBP Million)
Table 21.10 ImmunoPrecise Antibodies: Annual Revenues, 2016-9M 2020 (USD Million)
Table 21.11 Viva Biotech: Annual Revenues, 2016-2019 (RMB Million)
Table 21.12 Wuxi Biologics: Annual Revenues, 2015-2019 (RMB Billion)
Table 21.13 Antibody Discovery Platform Providers: Distribution by Year of Establishment
Table 21.14 Antibody Discovery Platform Providers: Distribution by Company Size
Table 21.15 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
Table 21.16 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Table 21.17 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Table 21.18 Antibody Discovery Platforms: Distribution by Animal Model Used
Table 21.19 Antibody Discovery Platforms: Distribution by Patent Availability
Table 21.20 ImmunoPrecise Antibodies: Annual Revenues, 2016-9M 2020 (USD Million)
Table 21.21 Ligand Pharmaceuticals: Annual Revenues, 2014-3M 2020 (USD Million)
Table 21.22 MorphoSys: Annual Revenues, 2014-3M 2020 (USD Million)
Table 21.23 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2020
Table 21.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
Table 21.26 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
Table 21.27 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
Table 21.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 21.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 21.30 Most Active Players: Distribution by Number of Partnerships
Table 21.31 Most Popular Technologies: Distribution by Number of Partnerships
Table 21.32 Partnership and Collaborations: Regional Distribution
Table 21.33 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2020
Table 21.34 Funding and Investment Analysis: Year-wise Distribution of Instances by Platform / Service Providers, (2016-2020)
Table 21.35 Funding and Investment Analysis: Cumulative Amount Invested, 2016-2020 (USD Million)
Table 21.36 Funding and Investment Analysis: Distribution by Instances across the Amount Invested, 2016-2020 (USD Million)
Table 21.37 Funding and Investment Analysis: Year-wise Distribution of the Amount Invested by Platform / Service Providers, 2016-2020 (USD Million)
Table 21.38 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2016-2020
Table 21.39 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2016-2020 (USD Million)
Table 21.40 Funding and Investment Analysis: Most Active Players, 2016–2020 (USD Million)
Table 21.41 Funding and Investment Analysis: Most Active Investors
Table 21.42 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 21.43 Global Antibody Discovery Services Market, 2020-2030 (USD Billion): Base, Conservative and Optimistic Scenarios
Table 21.44 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030: Base, Conservative and Optimistic Scenarios
Table 21.45 Antibody Discovery Services Market for Antigen Designing, 2020-2030
Table 21.46 Antibody Discovery Services Market for Hit Generation, 2020-2030
Table 21.47 Antibody Discovery Services Market for Lead Selection, 2020-2030
Table 21.48 Antibody Discovery Services Market for Lead Optimization, 2020-2030
Table 21.49 Antibody Discovery Services Market for Lead Characterization, 2020-2030
Table 21.50 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030: Base, Conservative and Optimistic Scenarios
Table 21.51 Antibody Discovery Services Market for Phage Display, 2020-2030
Table 21.52 Antibody Discovery Services Market for Yeast Display, 2020-2030
Table 21.53 Antibody Discovery Services Market for Hybridoma Method, 2020-2030
Table 21.54 Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030
Table 21.55 Antibody Discovery Services Market for Single Cell Based Method, 2020-2030
Table 21.56 Antibody Discovery Services Market for Other Methods, 2020-2030
Table 21.57 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030: Base, Conservative and Optimistic Scenarios
Table 21.58 Antibody Discovery Services Market for Humanized Antibodies, 2020-2030
Table 21.59 Antibody Discovery Services Market for Human Antibodies, 2020-2030
Table 21.60 Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030
Table 21.61 Antibody Discovery Services Market for Murine Antibodies, 2020-2030
Table 21.62 Global Antibody Discovery Services Market: Distribution by Region, 2020-2030: Base, Conservative and Optimistic Scenarios
Table 21.63 Antibody Discovery Services Market in North America, 2020-2030
Table 21.64 Antibody Discovery Services Market in Europe, 2020-2030
Table 21.65 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
Table 21.66 Global Antibody Discovery Platforms Market, 2020-2030 (USD Million): Base, Conservative and Optimistic Scenarios
Table 21.67 Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030 (USD Million): Base, Conservative and Optimistic Scenarios
Table 21.68 Antibody Discovery Platforms Market in North America, 2020-2030
Table 21.69 Antibody Discovery Platforms Market in Europe, 2020-2030
Table 21.70 Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030
Table 21.71 Humira®: Annual Sales, 2013-2019 (USD Billion)
Table 21.72 Keytruda®: Annual Sales, 2014-2019 (USD Billion)
Table 21.73 Herceptin®: Annual Sales, 2013-2019 (USD Billion)
Table 21.74 Avastin®: Annual Sales, 2013-2019 (USD Billion)
Table 21.75 Rituxan®: Annual Sales, 2013-2019 (USD Billion)
Table 21.76 Number of Licensing Deals, 2015- 2020
The following companies and organizations have been mentioned in the report:
Discounts available for multiple report purchases
sales@rootsanalysis.com